Cardiovascular

The project target was focused on the evaluation of the typical effects of the western desaese clinical trials in the last decades, where there is still a lack of consensus on the mechanisms and degree of beneficial impact of n-3 polyunsaturated fatty acids (n-3 PUFAs). The results are compiled in a structured model to predict ability of interaction between typical biomarkers and effects of n-3 polyunsaturated fatty acids. The primary result was selected to be the driver for a biomarket set, describing the individual effects on the metabolism of individual patients. A new productformulation is currently under development.

As an example of the Biomarker-Development to assess the impact of Omega-3 fatty acids by food-supplements on cardiovascular diseases, a typical set of paramters has been created.